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ABSTRACT 
Allogeneic hematopoietic stem cell transplant remains the only curative treatment for myelofibrosis. 
Most post-transplantation events occur during the first 2 years and hence we aimed to analyze the 
outcome of 2-year disease-free survivors. 1055 patients with myelofibrosis transplanted between 
1995 and 2014 and registered in the registry of the European Society for Blood and Marrow 
Transplantation were included. Survival was compared to the matched general population to 
determine excess mortality and the risk factors that are associated. In the 2-year survivors, Disease-
free survival was 64% (60-68%) and Overall Survival was 74% (71-78%) at 10 years, better in younger 
individuals and in women. Excess mortality was 14% (8-21%) in patients < 45 years and 33% (13-53%) 
in patients ≥ 65 years. The main cause of death was relapse of the primary disease. Graft versus Host 
Disease before 2 years decreased the risk of relapse. Multivariable analysis of excess mortality 
showed that age, male sex recipient, secondary myelofibrosis and no Graft Versus Host disease prior 
to the 2-year landmark increased the risk of excess mortality.  
This is the largest study to date analyzing long-term outcome in patients with myelofibrosis 
undergoing transplant. Overall it shows a good survival in patients alive and in remission at 2-years 
but the occurrence of late complications, including late relapses, infectious complications and 
secondary malignancies highlights the importance of screening and monitoring of long-term 
survivors. 
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INTRODUCTION 
Myelofibrosis (MF) is a malignant clonal disease which can be classified as either primary or 
secondary to either essential thrombocythemia (ET) or polycythemia Vera (PV). The clinical 
phenotype of MF is markedly heterogeneous and disease severity can be assessed by a number of 
different prognostic scoring systems. For example, utilizing Dynamic International Prognostic Scoring 
System “DIPSS-PLUS”, low, int-1, int-2 and high-risk patients have a median survival of 15 years, 6.5 
years, 35 months and 16 months, repectively
1
.  JAK-2 inhibitors, specifically ruxolitinib which remains 
the only licensed therapeutic agent in MF, alleviate many symptoms and even possibly increase 
survival,  are not considered curative
2–4
. Only allogeneic hematopoietic stem cells transplant (HSCT) 
has been proposed as curative, overall, HSCT has been reported to cure between 30 to 65% of these 
patients 
5–16
. One registry paper analyzed the timing to transplant in patients aged <65 years and 
concluded that those with intermediate-2 or high-risk disease are those who clearly benefit from 
transplantation strategies
17
. This analysis included transplant-episodes prior to the ruxolitinib era and 
the role of this agent on transplantation strategies remains under debate
18
. Early mortality (within 2 
years) after transplantation is known to be between 10 and 30% but to date, there is no study which 
has analyzed the outcome of MF transplanted patients after this early period. In contrast, long-term 
outcome studies have been published for  HSCT recipients who have more common disease types 
such as acute leukemia, lymphoma and chronic myeloid leukemia
19–24
. Understanding the long-term 
outcome for transplanted MF patients will facilitate enhanced monitoring and an increased 
awareness of the potential risks of relapse or indeed mortality, specifically when compared to the 
general population.  
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METHODS 
Patient selection 
Only patients from countries of which the population mortality tables are available in a uniform 
format through the Human Mortality Database allowing a sex and age matched comparison, and 
contributing more than twenty allogeneic transplantations for MF were included in the study. 
Patients younger than 18 years and those who were transplanted from an unrelated matched cord 
blood were excluded. Patients were analyzed at the time of their first allogeneic transplant only. 
2459 patients received a first allogeneic HCT between January 1995 and December 2014 for primary 
or secondary MF. A total of 1055 out of these 2459 patients were reported alive and free of their 
disease at 2-years after HSCT, these patients were considered for the study and called long-term 
(disease-free) survivors. These patients were transplanted in 178 centers in 15 countries.  
 
Definitions 
Relapse was defined as disease recurrence. Causes of death were classified as related to relapse if 
the patient experienced a relapse at any period during follow-up. Excess mortality was defined as the 
difference between mortality observed in the myelofibrosis landmark cohort and mortality in a 
matched cohort of the general population.  
 
Statistical analysis 
The endpoints of interest were overall survival (OS), disease-free survival (DFS), relapse/progression 
and non-relapse mortality (NRM) within the first 10 years after HSCT for patients alive and disease-
free at the two-year landmark (LM) after HSCT. For all outcomes, patients were considered to be at 
risk since this LM. Median follow-up was determined using the reverse Kaplan-Meier method. OS was 
defined as the time since landmark until death from any cause, with surviving patients censored at 
the time of last follow-up. Patients still at risk at 10 years after HSCT were administratively censored. 
DFS was defined as time to death or relapse/progression (whichever occurred first). OS and DFS were 
estimated using the Kaplan-Meier product limit estimation method, and differences in subgroups 
were assessed by the Log-Rank test. The cumulative incidences of relapse/progression (CIR) and non-
relapse mortality (NRM) were analyzed together in a competing risks framework
25
. Competing risks 
analyses were also applied to estimate the incidences of  (extensive) chronic GVHD (cGVHD) and 
secondary malignancies, each with the competing event death, at 10 years after HSCT. Previous 
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acute GVHD (aGVHD) in the landmark population was quantified as a simple proportion, since all 
cases of aGVHD occurred prior to the 2-year landmark time point. Cox proportional hazards 
regression was used to assess the impact of potential risk factors on OS, RFS, CIR and NRM. CIR and 
NRM were analysed in a competing risks framework in which the cause specific hazards (CSH) were 
modelled. 
Methods from relative survival were used to estimate the proportion of the deaths observed in our 
cohort which could be attributed to population causes (population mortality) and which to MF-
related causes, including HSCT and pre-treatment (excess mortality)
26,27
 Patients were matched by 
age, sex and country and year of HSCT to a cohort from the general population, for whom survival 
information was available in the population tables in the Human Mortality Database 
(http://www.mortality.org/). In univariable and multivariable analyses, The excess hazard of death 
was defined as the difference between the observed hazard in the patient cohort (this myelofibrosis 
cohort) and the hazard of the matched general population cohort. For multivariable analyses, we 
estimated Cox proportional hazards models for the excess hazard of death. Risk factors considered 
were age, sex, MF classification (primary versus secondary), conditioning intensity, Total Body 
Irradiation (TBI), donor type, stem cell source and previous GVHD (defined as the development of 
any type of GvHD between transplantation and the 2-year landmark). All estimates are reported with 
95% confidence intervals. All analyses were performed in SPSS version 23 and R 3.3.0 (https://cran.r-
project.org/), packages ‘survival’, ‘cmprsk’,  ‘prodlim’ and  ‘relsurv’. 
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RESULTS 
Characteristics of patients and transplant 
Characteristics of the entire patient cohort and the long-term survivors are shown in Table 1. Long-
term survivors were transplanted at a median age of 53.5 years, 837 (79%) patients had primary MF 
at the time of transplantation, 645 (63%) patients received a reduced intensity regimen and  471 
(45%) were  transplanted using an HLA-matched sibling donor.  
 
Outcome and predictors for outcome 
In the entire cohort including 2459 patients (without landmark), OS and DFS at 10 years were 41% 
(95%CI: 39-44) and 32% (95%CI: 30-35). Median follow-up in the landmark population was 49.7 
months (95%CI: 47-52). In the 1055 long-term survivors, 166 deaths were registered within 10 
years after HSCT. For all time periods, the most common cause of death was relapse of MF, followed 
by GVHD and infection, with a higher occurrence of infection-related deaths between 2- and 5-years 
post-transplant (Table 2). In the LM population, secondary cancers occurred in 34 patients before 
the landmark and in 87 patients after the landmark. This translated into a cumulative incidence in the 
LM population without cancer before the LM at 10 years of 14% (11-18) 10 years after the 
transplantation. The most frequent cancer was solid tumor (70% of whom 3 breast cancers), 
followed by acute leukemia or myelodysplastic syndrome (17%) and lymphoma (9%). 
Grade 2-4 acute GVHD had occurred in 23% of the LM patients (n=245). Before landmark, 56% (576 
patients) of the patients in the LM population had chronic GVHD of whom 263 patients had an 
extensive chronic GVHD. Among patients without chronic GVHD before the 2-year landmark, 
cumulative incidence of chronic extensive and limited GVHD were 13% (8-18) and 9% (5-12%), 
respectively. 10-year –OS and -DFS for 2-year survivors were 74% (71-78%) and 64% (60-68%) 
respectively (Figure 1. In these patients, relapse incidence and non-relapse mortality 10-years after 
transplant were estimated at 21% (17-24%) and 15% (12-18%) (Figure 1). Risk factors for mortality, 
DFS and relapse are shown in Table 3. Older age (p<0.001), type of myelofibrosis (higher risk for 
secondary myelofibrosis, p=0.01), male sex (p=0.004) and no GVHD before landmark (p=0.02) were 
associated with a significantly higher risk of mortality. Older age (p=0.033), RIC (p=0.017), male sex 
(p=0.003), donor other than an HLA-matched related donor (p=0.01) and no GVHD before landmark 
were associated significantly with lower DFS. Use of a donor other than HLA-matched related donor 
(p=0.008), RIC (p=0.042) and no GVHD occurrence before the landmark (p<0.001) significantly 
increased the risk for relapse.  
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Comparison to general population 
The excess mortality of the two-year landmark MF cohort was 21% (18-25%) at 10-years whereas its 
population mortality was 4% (4-4.2%) (Figure 2). Excess mortality was lower in younger patients and 
in female gender recipients but remained considerably greater than the matched population 
mortality (Figure 2). Excess mortality in the younger cohort (< 45 years) was 14% (8-21%) and 
population mortality was 1% (1-1.1%) at this age. In contrast, excess mortality in the older cohort 
(≥65 years) was 33% (13-53%) and population mortality was 12% (10-14%).  
 
Risk factors for late excess mortality 
A Cox model was developed to estimate the risk factors for excess mortality in the 2-year disease-
free survivors. Of note, the interpretation of the influence of variables in this landmark model applies 
to patients alive and free of the disease 2-years following transplantation. For instance, patients with 
severe GVHD may not survive the second year post-transplant but the subset of patients who 
survived with such GVHD are incorporated in the model. The multivariable model shows that older 
age, MF secondary to PV or ET, male gender recipient were risk factors for excess mortality (Table 4). 
In long-term survival, previous GVHD was protective for mortality (Table 4). The model highlights 
that age and sex, which were at higher risk in the general model, are still risk factors for excess 
mortality. Figure 3 shows changes in the hazard of excess mortality of for reference patients 
according to Cox model (variables from the Table 4) transplanted at the age of 50 years, the hazards 
are given for men and for women separately. We can see that there is a decline in hazard of excess 
mortality over time post HSCT but after 3 years (5 years post-transplant), there is a kind of plateau. 
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DISCUSSION 
This EBMT report of 1055 patients alive and in remission at 2-years after HSCT is the largest study of 
long-term post-transplant outcome in patients with MF. Results indicate that survival 10 years after 
transplantation in these 2-year survivors is 74% but also that the mortality rate does not decrease to 
that expected in the general population. This is the first long-term study in myelofibrosis with the 
method of landmark analysis. Previously, it has been reported in other diseases that long-term 
outcome in transplanted patients remains lower than expected in general population (except in 
aplastic anemia)
20
 
21
. Our results can be considered disappointing as compared to previous 
publications, especially from CIBMTR, but the median age was 2 decades higher in our cohort which 
could explain the higher long-term mortality. Indeed, we could confirm that in a subgroup of patients 
younger than 45 years, OS was very good OS at 86% 10-years after transplantation. Two additional 
recent long-term analyses in patients with chronic malignancies (chronic lymphocytic leukemia (CLL) 
and myelodysplastic syndrome (MDS)) from EBMT registry included patients with a median age 
closer to MF patients, estimated long-term survival lower than in this MF cohort
2724
. Similar risk 
factors for mortality were found with a better OS in women and in younger
24
 patients. The higher risk 
in male recipients is not totally elucidated but usually it is thought to be possibly due to higher risk 
behavior and also to higher propensity towards comorbidities such as cardio-vascular disease
28
. In 
contrast, an EBMT study led in patients with acute myeloid leukemia did not show age and sex were 
predictors for OS
29
. 
Akin to other malignant disorders, late relapse was the leading cause of death in MF patients 
following HSCT 
19–22,24,29
. Relapse incidence at 10-years after transplant in the long-term survivors is 
21%, concordant with that expected in other malignant disorders and highlights that even if the 
relapse risk decreases over time, it can still occur late after transplant. Many studies have reported 
that relapse risk is related to the disease risk at the time of transplant. Unfortunately, due to the 
retrospective registry-based nature of this study, we did not have sufficient data to calculate a 
relevant IPSS and so unfortunately could not analyze this aspect. However, we observed that the 
relapse risk was higher in patients who received a RIC, which could be expected but were surprised 
that in long-term survivors, the intensity of the regimen still had some impact. In acute myeloid 
leukemia, the EBMT long-term study, did not find that regimen intensity still has influence on late 
relapse
29
. Occurrence of acute or chronic GVHD before the landmark was the strongest factor 
preventing relapse in long-term survivors
17,1817,1817,1817,18
. While in many other studies, GVHD 
increased the risk of late deaths, we failed to confirm this assertion in our MF cohort
19,20
. GVHD 
before landmark (2 years) in long-term survivors was protective for both relapse risk as well as for 
mortality. Of course, from this analysis, we cannot extrapolate that GVHD is needed to improve long-
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term outcome, because patients with GVHD leading to death in the first 2 years of transplant have 
been excluded from the study, per se.  
The weakness for GVHD analysis within this cohort was that we could not delineate the risk of “active 
GVHD” because we had no data regarding GVHD resolution, albeit that it is probable that patients 
still alive at 2 years with chronic GVHD were those with the less severe GVHD. The vast majority of 
patients had onset of chronic GVHD before the landmark but some patients had also a late onset. 
Finally, the majority of survivors suffered (or had suffered) from chronic GVHD which may alter their 
quality of life and it is noteworthy that even if they are in remission from their myelofibrosis, patients 
could have a chronic GVHD which can be a cause of death especially before 5 years.  
Infectious complications remained a frequent cause of death between 2 and 5 years post-transplant. 
It has been previously reported that splenectomy before transplant increased the risk of late severe 
infection which may in part contribute to these findings within the MF-cohort
30
. This high risk of 
lethal infection should be taken into account in long-term monitoring strategies and highlights the 
importance of appropriate anti-infective prophylaxis
31,32
.  
Second malignancies were also the cause of very late deaths, justifying long-term monitoring and 
cancer prevention in this population. After 5-years, 16% of deaths were due to second malignancies 
and at 10 years, cumulative incidence of secondary cancer was 14%. We could not analyze specific 
risk factors for second malignancies due to the small numbers involved.  There are few long-term 
survivors for non-transplanted higher risk MF so there is no data for long-term secondary cancers 
within that population is unknown. It is hard to determine how the transplantation process increases 
the risk of cancer but chemotherapy, radiotherapy, immune deficiency, chronic GVHD, genetic 
susceptibility as well as age can cumulatively contribute towards an increased susceptibility. 
To conclude, patients with MF have good survival when alive and in remission 2-years after 
transplantation, especially younger and female recipients. Severe late complications and late 
relapses should be monitored and prevention highlighted in order to reduce life threatening 
complications. Lifelong follow-up is required to optimize long-term outcomes
33
. 
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Table 1. Patients and transplant characteristics 
 Whole cohort 
Numbers            % 
2-year land mark 
Numbers         % 
Total number of patients 2459  1055  
Disease at time of transplant 
   Primary myelofibrosis 
   Secondary myelofibrosis 
   Transformation into acute leukemia 
 
1904 
421 
134 
 
78 
17 
5 
 
837 
188 
30 
 
79 
18 
3 
Median age at HSCT, years 
   Age < 45 years 
   Age 45-54 years 
   Age 55-64 years 
   Age >= 65 years 
55 
355 
729 
1137 
238 
 
14 
30 
46 
10 
53.5 
193 
351 
426 
85 
 
19 
33 
40 
8 
Interval primary diagnosis and transplant 
Median    
< 12 months 
>=12 months 
 
 
743 
1716 
 
 
30 
70 
 
26.7 
308 
747 
 
 
29 
71 
Conditioning regimen 
  Reduced intensity 
  Standard 
  Total body irradiation Yes 
  No        
 
1502 
877 
423 
2015 
 
63 
37 
17 
83 
 
645 
378 
191 
855 
 
63 
37 
18 
82 
Source of stem cells 
   Marrow 
   Blood 
 
332 
2127 
 
14 
86 
 
150 
905 
 
14 
86 
HLA matched sibling donor 
Other 
1022 
1379 
43 
57 
471 
565 
45 
55 
Unreported data found for regimen and type of donor but always < 4%. 
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Table 2. Causes of mortality after 2 years 
Years from transplant 2 - 5y  >5 - 10y 
 N % N % 
Relapse/progression 33 41 30 61 
Secondary malignancy* 9 11 8 16 
GvHD 18 22 9 19 
Infection 17 21 2 4 
Organ damage/toxicity 4 5  
 
Unknown 28  8  
Total 
109  57  
* including post-transplant lymphoproliferative disease 
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Table 3. Multivariable (cause-specific) Cox proportional hazards models for outcomes in the period between 2 and 10 years after HSCT for patients alive and 
disease-free at 2 years after HSCT  
Variables Overall survival P-value Disease-free survival P-value Relapse P-value 
 HR (95%CI)  HR (95%CI)  HR (95%CI)  
Age (per decade) 1.45 (1.19- 1.76) <0.001 1.18 (1.01 - 1.37) 0.033 1.16 (0.96 - 1.42) 0.131 
Patient sex 
   Male 
   Female 
 
1 
0.58 (0.4 - 0.84) 
 
 
0.004 
 
1 
0.65 (0.49 - 0.87) 
 
 
0.003 
 
1 
0.79 (0.55 - 1.14) 
 
 
0.205 
MF classification 
   PMF 
   SMF 
 
1 
1.66 (1.13 - 2.44) 
 
 
0.01 
 
1 
1.35 (0.97 - 1.88) 
 
 
0.071 
 
1 
1.07 (0.67 - 1.7) 
 
 
0.78 
Source of stem cells 
  Marrow 
  PB    
 
1 
0.83 (0.51 - 1.34) 
 
 
0.442 
 
1 
0.77 (0.52 - 1.13) 
 
 
0.178 
 
1 
0.67 (0.41 - 1.09) 
 
 
0.107 
Cond. reg. intensity 
   MAC 
   RIC 
 
1 
1.17 (0.79 - 1.73) 
 
 
0.434 
 
1 
1.48 (1.07 - 2.04) 
 
 
0.017 
 
1 
1.54 (1.02 - 2.35) 
 
 
0.042 
Cond. reg. with 
   Chemo only 
   TBI 
 
1 
1.25 (0.81 - 1.93) 
 
 
0.322 
 
1 
1.28 (0.89 - 1.82) 
 
 
0.18 
 
1 
1.28 (0.8 - 2.06) 
 
 
0.305 
Type of donor 
   Matched sibling 
   Unrelated 
 
1 
1.08 (0.77 - 1.51) 
 
 
0.669 
 
1 
1.43 (1.09 - 1.89) 
 
 
0.011 
 
1 
1.65 (1.14 - 2.39) 
 
 
0.008 
Any previous GVHD 0.67 (0.48 - 0.94) 0.02 0.62 (0.47 - 0.81) 0.001 0.42 (0.3 - 0.6) <0.001 
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Table 4. A multivariable Cox proportional hazards model for excess mortality in the period between 2 and 10 years after HSCT for patients alive and disease-
free at 2 years after HSCT  
 
 Hazard ratio 95% confidence 
interval 
P-value 
Patient sex 
   Male 
   Female 
 
1 
0.62 
 
 
0.41 - 0.93 
 
 
0.022 
Age (per decades) 1.35 1.08 - 1.69 0.008 
Disease 
   Primary myelofibrosis 
   Secondary myelofibrosis 
 
1 
1.81 
 
 
1.18 - 2.78 
 
 
0.007 
Standard 
Reduced intensity regimen 
1 
1.16 
 
0.74 - 1.82 
 
0.527 
No TBI 
TBI in regimen 
1 
1.25 
 
0.75 - 2.08 
 
0.384 
Donor 
   Matched sibling donor 
   Other donor 
 
1 
1.1 
 
 
0.75 - 1.63 
 
 
0.623 
Source of stem cells 
   Marrow 
   Blood 
 
1 
0.83 
 
 
0.48 - 1.44 
 
 
0.515 
GVHD 
   No 
   Any 
    
 
1 
0.65 
 
 
0.44 - 0.96 
 
 
0.031 
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Legends to Figures 
Figure 1. Outcome of myelofibrosis patient from landmark time 
Left panel: overall Survival and Disease Free Survival from landmark time. Solid line is OS, dashed line 
is DFS. Right panel: relapse incidence and non-relapse mortality. Solid line is relapse, dashed line is 
non-relapse mortality. 
Figure 2. Mortality in myelofibrosis compared to general population 
 Top figure: The plots show mortality of the disease-free survivors (black line) and in general 
population (grey line) mortality. Middle figure: The plots show mortality of the myelofibrosis patients 
according to sex (black solid line in female and dashed line in male) and the mortality in the general 
population (grey lines). Down figure: the plots show mortality of disease-free survivors (black lines) 
and general population (grey lines) by age categories 
Figure 3. Hazard rate for excess risk of mortality with post-transplant time 
The curves show hazard rates for two reference patients, based on the Cox model for the excess 
hazard. They are both 50 years at HSCT, had primary MF, received standard conditioning, no TBI, a 
matched sibling donor, marrow as source of stem cells and no previous GVHD. The solid line shows a 
male patient and the dashed line a female patient. 
 



